Analysts Set Adaptimmune Therapeutics plc (NASDAQ:ADAP) PT at $1.83

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) have been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $1.83.

A number of equities research analysts recently commented on the company. Scotiabank lowered their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research report on Friday, March 21st. Guggenheim lowered their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a report on Wednesday, March 26th. Wells Fargo & Company dropped their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research report on Friday, March 21st. Jones Trading downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 11th. Finally, StockNews.com initiated coverage on shares of Adaptimmune Therapeutics in a research report on Monday, April 14th. They set a “buy” rating on the stock.

Institutional Trading of Adaptimmune Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC increased its stake in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares during the last quarter. Virtu Financial LLC grew its holdings in Adaptimmune Therapeutics by 27.5% during the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 21,769 shares during the period. FMR LLC increased its position in Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after buying an additional 50,419 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares during the period. Finally, Two Seas Capital LP purchased a new position in shares of Adaptimmune Therapeutics during the 4th quarter valued at $7,992,000. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Down 0.7 %

NASDAQ:ADAP opened at $0.24 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a one year low of $0.20 and a one year high of $1.48. The company has a market cap of $61.27 million, a PE ratio of -1.08 and a beta of 2.84. The firm has a 50-day moving average of $0.39 and a 200-day moving average of $0.58.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The company had revenue of $3.22 million for the quarter, compared to the consensus estimate of $16.56 million. As a group, equities research analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.